Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSPM OTCMKTS:EPRSQ OTCMKTS:PFSCF OTCMKTS:PZRXQ OTCMKTS:STLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSPMBiostar Pharmaceuticals$0.03$0.00▼$0.05N/A51.7411 shsN/AEPRSQEPIRUS Biopharmaceuticals$0.00$0.00▼$0.00N/AN/AN/AN/APFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APZRXQPhaseRx$0.00$0.00▼$0.00N/AN/AN/AN/ASTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSPMBiostar Pharmaceuticals0.00%0.00%0.00%+49,900.00%+∞EPRSQEPIRUS Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PZRXQPhaseRx0.00%0.00%0.00%0.00%-50.00%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSPMBiostar Pharmaceuticals$0.03$0.00▼$0.05N/A51.7411 shsN/AEPRSQEPIRUS Biopharmaceuticals$0.00$0.00▼$0.00N/AN/AN/AN/APFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APZRXQPhaseRx$0.00$0.00▼$0.00N/AN/AN/AN/ASTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSPMBiostar Pharmaceuticals0.00%0.00%0.00%+49,900.00%+∞EPRSQEPIRUS Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PZRXQPhaseRx0.00%0.00%0.00%0.00%-50.00%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSPMBiostar Pharmaceuticals 0.00N/AN/AN/AEPRSQEPIRUS Biopharmaceuticals 0.00N/AN/AN/APFSCFProMetic Life Sciences 0.00N/AN/AN/APZRXQPhaseRx 0.00N/AN/AN/ASTLTSpotlight Innovation 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSPMBiostar PharmaceuticalsN/AN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/AN/APFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08PZRXQPhaseRxN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSPMBiostar PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/APFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/APZRXQPhaseRxN/AN/A0.00N/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSPMBiostar PharmaceuticalsN/AN/AN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/APZRXQPhaseRxN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSPMBiostar PharmaceuticalsN/AN/AN/AEPRSQEPIRUS BiopharmaceuticalsN/AN/AN/APFSCFProMetic Life SciencesN/A0.950.71PZRXQPhaseRxN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSPMBiostar PharmaceuticalsN/AEPRSQEPIRUS BiopharmaceuticalsN/APFSCFProMetic Life Sciences0.10%PZRXQPhaseRxN/ASTLTSpotlight InnovationN/AInsider OwnershipCompanyInsider OwnershipBSPMBiostar Pharmaceuticals17.20%EPRSQEPIRUS Biopharmaceuticals13.06%PFSCFProMetic Life SciencesN/APZRXQPhaseRx44.69%STLTSpotlight InnovationN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSPMBiostar Pharmaceuticals200N/AN/ANot OptionableEPRSQEPIRUS Biopharmaceuticals70N/AN/ANot OptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionablePZRXQPhaseRx20N/AN/ANot OptionableSTLTSpotlight Innovation4N/AN/ANot OptionableSTLT, PFSCF, PZRXQ, EPRSQ, and BSPM HeadlinesRecent News About These CompaniesSector Spotlight: Industry digests $17B EchoStar-SpaceX spectrum license dealSeptember 12, 2025 | msn.comLarge turnout for Entrepreneur Spotlight event in SpringfieldSeptember 12, 2025 | wwlp.comWRX launches WTM Spotlight with an inaugural event in Saudi ArabiaSeptember 10, 2025 | travelmole.comTWTM Spotlight in Saudi Arabia – A New Travel Trade Show To Be Launched by RXSeptember 10, 2025 | eturbonews.comEWTM Spotlight Debuts in Riyadh to Support Saudi’s Tourism Vision 2030September 10, 2025 | ftnnews.comFTeacher Spotlight: See all the teachers featuredSeptember 9, 2025 | newsday.comNCooper Companies (NASDAQ:COO) and Spotlight Innovation (OTCMKTS:STLT) Critical ReviewSeptember 9, 2025 | americanbankingnews.comNanlite Global Spotlight: GT40 & Timeless Audi R8 V10September 8, 2025 | msn.comSpotlight on the News: K-12 education, road funding, defense spending, MI's budget battleSeptember 7, 2025 | wxyz.comWEquity vs Spotlight: How the legal battle unfoldedSeptember 3, 2025 | thestage.co.ukTVictory For Spotlight: Equity’s Landmark Claim Against Casting Directory Thrown Out By UK High Court; Union Considering AppealSeptember 3, 2025 | deadline.comDActors Union Equity Blasted by ‘Oldest Ally' Spotlight After Losing ‘Cynical, Performative and Expensive' Court CaseSeptember 3, 2025 | msn.comCold Hill Elementary named 2025 Spotlight SchoolAugust 29, 2025 | yahoo.comZ launches Zee Spotlight: Hyundai first partner for advertising offeringAugust 29, 2025 | exchange4media.comEZ launches Zee Spotlight as part of Z RISE initiativeAugust 29, 2025 | socialsamosa.comSZEEL unveils ‘Zee Spotlight’, a new ad innovation across GECs and movie channelsAugust 28, 2025 | bestmediainfo.comB"Spotlight on City Workers" Series Honors Philadelphia's Unsung Heroes in Municipal ServiceAugust 27, 2025 | hoodline.comHSolar Spotlight: Empowering Utility-Scale Solar from the Ground UpAugust 20, 2025 | solarpowerworldonline.comSKuCoin Spotlight Drives AI Gaming Innovation: Launches Token Sale for AKEDO with Early Access, Exclusive Benefits, and Principal ProtectionAugust 18, 2025 | tmcnet.comFuture of Windows: Microsoft Execs Spotlight Multimodal Interactions, Copilot+ PCs, Secure Cloud DevicesAugust 15, 2025 | techrepublic.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTLT, PFSCF, PZRXQ, EPRSQ, and BSPM Company DescriptionsBiostar Pharmaceuticals OTCMKTS:BSPMBiostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.EPIRUS Biopharmaceuticals OTCMKTS:EPRSQEPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.PhaseRx OTCMKTS:PZRXQPhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.Spotlight Innovation OTCMKTS:STLTSpotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
